EP300 and cancer: Two CBP/p300 inhibitors are currently being tested in clinical trials as potential targets for treatment of cancer patients: CCS1477 (ClinicalTrials.gov identifier: NCT03568656) and FT-7051 (ClinicalTrials.gov identifier: NCT04575766).